Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
Sizheng Steven Zhao, David R. Riley, Gema Hernandez, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 2
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 12
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester, Jacques‐Eric Gottenberg, Roberto Caporali, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225759
Open Access | Times Cited: 7
Rheumatologische Versorgung in Deutschland
Joseph M. Braun, K. Albrecht, Johanna Callhoff, et al.
Zeitschrift für Rheumatologie (2024) Vol. 83, Iss. S2, pp. 249-284
Closed Access | Times Cited: 6
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
Jérôme Avouac, Hafid Ait‐Oufella, Caroline Habauzit, et al.
Rheumatology and Therapy (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
Xavier Mariette, Sven Borchmann, Sandrine Aspeslagh, et al.
RMD Open (2025) Vol. 11, Iss. 1, pp. e005033-e005033
Open Access
Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study
Chung-Mao Kao, Yen–Ju Chen, Yi‐Ming Chen, et al.
Therapeutic Advances in Musculoskeletal Disease (2025) Vol. 17
Open Access
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Ennio Giulio Favalli, Gabriella Maioli, Roberto Caporali
Drugs (2024) Vol. 84, Iss. 8, pp. 877-894
Open Access | Times Cited: 4
Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
Elena Bartoloni, Fabio Cacciapaglia, Gian Luca Erre, et al.
Autoimmunity Reviews (2025), pp. 103760-103760
Closed Access
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis
Elena Myasoedova, Eric L. Matteson
Current Opinion in Rheumatology (2024) Vol. 36, Iss. 3, pp. 203-208
Closed Access | Times Cited: 2
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003885-e003885
Open Access | Times Cited: 2
Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis
Nicoletta Luciano, Elisa Barone, Suraj Timilsina, et al.
Clinical Reviews in Allergy & Immunology (2023) Vol. 65, Iss. 3, pp. 403-419
Closed Access | Times Cited: 5
Sex-specific aspects in rheumatology
Katinka Albrecht, Sarah Ohrndorf, Anja Strangfeld
Zeitschrift für Rheumatologie (2024)
Closed Access | Times Cited: 1
Role of rheumatoid arthritis registries worldwide: What have they taught us?
Paul Studenic, Yvette Meißner, Lianne Kearsley‐Fleet, et al.
Best Practice & Research Clinical Rheumatology (2024), pp. 102017-102017
Open Access | Times Cited: 1
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis – why cardiovascular risk factors do not equate to overt risk
Anna Felis-Giemza, Mateusz Moskal, Krzysztof Proc, et al.
Reumatologia/Rheumatology (2024) Vol. 61, Iss. 6, pp. 414-423
Open Access
2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs
Muhammad Shoaib Momen Majumder, A.T.M. Tanveer Hasan, Minhaj Rahim Choudhury, et al.
Cureus (2024)
Open Access
Sicherheit und Wirksamkeit der Therapie der rheumatoiden Arthritis im Alter: Was sagen Register- und Routinedaten?
Anja Strangfeld, A. Zink
Aktuelle Rheumatologie (2024) Vol. 49, Iss. 05, pp. 301-309
Closed Access
Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis
Jing He, Yifan Wang, Qinghong Liu, et al.
Best Practice & Research Clinical Rheumatology (2024), pp. 102018-102018
Closed Access
Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
Elisabet Castañeda-Estévez, C Vergara-Dangond, Martina Steiner, et al.
Pharmaceuticals (2024) Vol. 18, Iss. 1, pp. 22-22
Open Access
Page 1

Scroll to top